Can pre-treatment inflammatory biomarker levels predict the response of tocilizumab therapy in COVID-19 patients?
-
Published:2023-12-01
Issue:4
Volume:65
Page:145-151
-
ISSN:1302-0471
-
Container-title:Gulhane Medical Journal
-
language:
-
Short-container-title:GMJ
Author:
Kaya Mehmet NurORCID,
Tecer DuyguORCID,
Çınar MuhammetORCID,
Bıçakcı FahrettinORCID,
Tekgöz EmreORCID,
Çolak SedaORCID,
Yılmaz SedatORCID
Publisher
Galenos Yayinevi
Reference33 articles.
1. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review;Wiersinga;JAMA,2020
2. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options;van Eijk;J Pathol,2021
3. COVID-19 cytokine storm: the interplay between inflammation and coagulation;RJ;Lancet Respir Med,2020
4. The role of IL-6 and IL-6 blockade in COVID-19;Potere;Expert Rev Clin Immunol,2021
5. A systematic review and meta-analysis on blood levels of cytokines/chemokines in COVID-19 cases;Ramezani;Gulhane Medical Journal,2022